Zai Lab Announces Positive Phase III Data for Krazati in KRASG12C-mutated NSCLC, Plans NDA Filing in China
Zai Lab (NASDAQ: ZLAB; HKG: 9688), a China-based biotech company, has announced positive Phase III...
Company
Alexion’s Voydeya Earns FDA Nod as Add-on Therapy for PNH-Associated Extravascular Hemolysis
Alexion, the rare disease unit of AstraZeneca (AZ; NASDAQ: AZN) based in the UK, has...
Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation
Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market,...
Huihe Healthcare’s Vispearl Microsphere Earns Marketing Approval in China for Innovative Cancer Treatment
Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured...
J&J’s Nipocalimab Fast-Tracked by FDA for Reducing FNAIT Risk in Pregnant Adults
The US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (J&J; NYSE: JNJ)...
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...
Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...
Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center
Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has...
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...
Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China
Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has...
ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a...
Junshi Biosciences Gets Green Light for Global Phase III Study of Tifcemalimab Combination Therapy in LS-SCLC
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877), a leading biotech company based in China, has...
FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi
Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...
Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC
Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...
China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology
The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9...
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost...
AstraZeneca’s AKT Inhibitor Truqap Approved in Japan for HR+, HER2- Breast Cancer
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has registered with Japan’s Ministry of Health,...
Kobayashi Pharmaceutical Faces Expanding Scandal Over Contaminated Red Yeast Rice Supplements
Kobayashi Pharmaceutical, based in Japan, is facing a deepening scandal over contaminated red yeast rice...